Tumor Biology

, Volume 35, Issue 1, pp 171–177 | Cite as

The CCND1 G870A polymorphism and susceptibility to bladder cancer

  • Jing Li
  • Fei Luo
  • Hongtuan Zhang
  • Liang Li
  • Yong Xu
Research Article


Published studies on the association between cyclin D1 (CCND1) G870A polymorphism and bladder cancer risk have yielded conflicting results. Thus, a systemic review and meta-analysis of published studies were performed to assess the possible association. All eligible studies of G870A polymorphism and bladder cancer risk were collected from the PubMed and the Cochrane Library. Statistical analyses were performed by Review Manager 5.0 and Stata 11.0. Significant association between G870A polymorphism and bladder cancer susceptibility was found under recessive model in overall population (OR = 1.21, 95 % CI 1.01–1.45, P = 0.04). When stratifying for the race, our analysis suggested that CCND1 G870A was associated with bladder cancer risk in Asians when using homogeneous codominant (OR = 1.72, 95 % CI 1.34–2.20, P < 0.0001), recessive (OR = 1.46, 95 % CI 1.21–1.77, P < 0.0001), dominant (OR = 1.36, 95 % CI 1.10–1.69, P = 0.004), and allelic models (OR = 1.30, 95 % CI 1.15–1.47, P < 0.0001) to analyze the data. However, no significant associations were found in Caucasians. After stratifying the studies by control source, G870A polymorphism was significantly associated with bladder cancer risk under recessive model (OR = 1.31, 95 % CI 1.03–1.67, P = 0.03) in hospital-based case–control studies, but not in population-based case–control studies. This meta-analysis suggested that G870A polymorphism most likely contributes to increased susceptibility to bladder cancer in the overall population, hospital-based case–control studies, and Asians.


Cyclin D1 Polymorphism Bladder cancer Meta-analysis Association 


Conflicts of interest

The authors declared that they have no competing interests.


  1. 1.
    Mohanty NK. Cancer urinary bladder etiopathology and its management. Heal Adm. 2005;17:126–31.Google Scholar
  2. 2.
    Matullo G, Guarrera S, Sacerdote C, Polidoro S, Davico L, Gamberini S, et al. Polymorphisms/haplotypes in DNA repair genes and smoking: a bladder cancer case–control study. Cancer Epidemiol Biomark Prev. 2005;14:2569–78.CrossRefGoogle Scholar
  3. 3.
    Cassidy A, Wang W, Wu X, Lin J. Risk of urinary bladder cancer: a case–control analysis of industry and occupation. BMC Cancer. 2009;9:443.PubMedCentralPubMedCrossRefGoogle Scholar
  4. 4.
    Sidransky D, Frost P, von Eschenbach A, Oyasu R, Preisinger AC, Vogelstein B. Clonal origin of bladder cancer. N Engl J Med. 1992;326:737–40.PubMedCrossRefGoogle Scholar
  5. 5.
    Mao L, Lee DJ, Tockman MS, Erozan YS, Askin F, Sidransky D. Microsatellite alterations as clonal markers for the detection of human cancers. Proc Natl Acad Sci U S A. 1994;91:9871–5.PubMedCentralPubMedCrossRefGoogle Scholar
  6. 6.
    Habuchi T, Takahashi R, Yamada H, Kakehi Y, Sugiyama T, Yoshida O. Metachronous multifocal development of urothelial cancers by intraluminal seeding. Lancet. 1993;342:1087–8.PubMedCrossRefGoogle Scholar
  7. 7.
    Sgambato A, Migaldi M, Faraglia B, De Aloysio G, Ferrari P, Ardito R, et al. Cyclin D1 expression in papillary superficial bladder cancer: its association with other cell cycle-associated proteins, cell proliferation, and clinical outcome. Int J Cancer. 2002;97:671–8.PubMedCrossRefGoogle Scholar
  8. 8.
    Suwa Y, Takano Y, Iki M, Takeda M, Asakura T, Noguchi S, et al. Cyclin D1 protein overexpression is related to tumor differentiation, but not to tumor progression or proliferative activity, in transitional cell carcinoma of the bladder. J Urol. 1998;160:897–900.PubMedCrossRefGoogle Scholar
  9. 9.
    Yang CH, Hung WC, Wang SL, Kang WY, Chen WT, Huang YC, et al. Immunoexpression and prognostic role of hTERT and cyclin D1 in urothelial carcinoma. APMIS. 2008;116:309–16.PubMedCrossRefGoogle Scholar
  10. 10.
    Lee CC, Yamamoto S, Morimura K, Wanibuchi H, Nishisaka N, Ikemoto S, et al. Significance of cyclin D1 overexpression in transitional cell carcinomas of the urinary bladder and its correlation with histopathologic features. Cancer. 1997;79:780–9.PubMedCrossRefGoogle Scholar
  11. 11.
    Shin KY, Kong G, Kim WS, Lee TY, Woo YN, Lee JD. Overexpression of cyclin D1 correlates with early recurrence in superficial bladder cancers. Brit J Cancer. 1997;75:1788–92.PubMedCrossRefGoogle Scholar
  12. 12.
    Betticher DC, Thatcher N, Altermatt HJ, Hoban P, Ryder WD, Heighway J. Alternate splicing produces a novel cyclin D1 transcript. Oncogene. 1995;11:1005–11.PubMedGoogle Scholar
  13. 13.
    Hosokawa Y, Arnold A. Mechanism of cyclin D1 (CCND1, PRAD1) overexpression in human cancer cells: analysis of allele-specific expression. Genes Chromosome Cancer. 1998;22:66–71.CrossRefGoogle Scholar
  14. 14.
    Mantel N, Haenszel W. Statistical aspects of the analysis of data from retrospective studies of disease. J Natl Cancer Inst. 1959;22:719–48.PubMedGoogle Scholar
  15. 15.
    DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials. 1986;7:177–88.PubMedCrossRefGoogle Scholar
  16. 16.
    Egger M, Davey Smith G, Schneider M, Minder C. Bias in meta-analysis detected by a simple graphical test. BMJ. 1997;315:629–34.PubMedCrossRefGoogle Scholar
  17. 17.
    Chung CJ, Huang CJ, Pu YS, Su CT, Huang YK, Chen YT, et al. Polymorphisms in cell cycle regulatory genes, urinary arsenic profile, and urothelial carcinoma. Toxicol Appl Pharmacol. 2008;232:203–9.PubMedCrossRefGoogle Scholar
  18. 18.
    Lin HH, Ke HL, Hsiao KH, Tsai CW, Wu WJ, Bau DT, et al. Potential role of CCND1 G870A genotype as a predictor for urothelial carcinoma susceptibility and muscle-invasiveness in Taiwan. Chin J Physiol. 2011;54:196–202.PubMedCrossRefGoogle Scholar
  19. 19.
    Yuan L, Gu X, Shao J, Wang M, Wang M, Zhu Q, et al. Cyclin D1 G870A polymorphism is associated with risk and clinicopathologic characteristics of bladder cancer. DNA Cell Biol. 2010;29:611–7.PubMedCrossRefGoogle Scholar
  20. 20.
    Gangwar R, Mittal RD. Association of selected variants in genes involved in cell cycle and apoptosis with bladder cancer risk in North Indian population. DNA Cell Biol. 2010;29:349–56.PubMedCrossRefGoogle Scholar
  21. 21.
    Ye Y, Yang H, Grossman HB, Dinney C, Wu X, Gu J. Genetic variants in cell cycle control pathway confer susceptibility to bladder cancer. Cancer. 2008;112:2467–74.PubMedCrossRefGoogle Scholar
  22. 22.
    Sanyal S, Festa F, Sakano S, Zhang Z, Steineck G, Norming U, et al. Polymorphisms in DNA repair and metabolic genes in bladder cancer. Carcinogenesis. 2004;25:729–34.PubMedCrossRefGoogle Scholar
  23. 23.
    Cortessis VK, Siegmund K, Xue S, Ross RK, Yu MC. A case–control study of cyclin D1 CCND1 870A—>G polymorphism and bladder cancer. Carcinogenesis. 2003;24:1645–50.PubMedCrossRefGoogle Scholar
  24. 24.
    Wang L, Habuchi T, Takahashi T, Mitsumori K, Kamoto T, Kakehi Y, et al. Cyclin D1 gene polymorphism is associated with an increased risk of urinary bladder cancer. Carcinogenesis. 2002;23:257–64.PubMedCrossRefGoogle Scholar
  25. 25.
    Zhang H, Xu Y, Zhang Z, Liu R, Ma B. Association between COX-2 rs2745557 polymorphism and prostate cancer risk: a systematic review and meta-analysis. BMC Immunol. 2012;13:14.PubMedCentralPubMedCrossRefGoogle Scholar
  26. 26.
    Wu GY, Hasenberg T, Magdeburg R, Bönninghoff R, Sturm JW, Keese M. Association between EGF, TGF-beta1, VEGF gene polymorphism, and colorectal cancer. World J Surg. 2009;33:124–9.PubMedCrossRefGoogle Scholar
  27. 27.
    Zhang H, Ma H, Xu Y, Li L. Association of SMAD7 rs12953717 polymorphism with cancer: a meta-analysis. PLoS One. 2013;8:e58170.PubMedCentralPubMedCrossRefGoogle Scholar
  28. 28.
    Vízkeleti L, Ecsedi S, Rákosy Z, Orosz A, Lázár V, Emri G, et al. The role of CCND1 alterations during the progression of cutaneous malignant melanoma. Tumor Biol. 2012;33:2189–99.CrossRefGoogle Scholar
  29. 29.
    Liu J, Liao Q, Zhang Y, Sun S, Zhong C, Liu X. Cyclin D1 G870A polymorphism and lung cancer risk: a meta-analysis. Tumor Biol. 2012;33:1467–76.CrossRefGoogle Scholar
  30. 30.
    Yang Y, Wang F, Shi C, Zou Y, Qin H, Ma Y. Cyclin D1 G870A polymorphism contributes to colorectal cancer susceptibility: evidence from a systematic review of 22 case–control studies. PLoS One. 2012;7:e36813.PubMedCentralPubMedCrossRefGoogle Scholar
  31. 31.
    Cui J, Shen L, Wang Y. Specific CCND1 G870A alleles associated with breast cancer susceptibility: a meta-analysis of 5,528 cases and 5,353 controls. Asian Pac J Cancer Prev. 2012;13:5023–5.PubMedCrossRefGoogle Scholar

Copyright information

© International Society of Oncology and BioMarkers (ISOBM) 2013

Authors and Affiliations

  • Jing Li
    • 1
    • 2
  • Fei Luo
    • 1
  • Hongtuan Zhang
    • 1
  • Liang Li
    • 3
  • Yong Xu
    • 1
    • 4
  1. 1.Department of Urology, Tianjin Key Lab of UrologySecond Affiliated Hospital of Tianjin Medical UniversityTianjinChina
  2. 2.Department of urology, Henan Cancer HospitalAffiliated Cancer Hospital of Zhengzhou UniversityHenanChina
  3. 3.Department of RadiologySecond Affiliated Hospital of Tianjin Medical UniversityTianjinChina
  4. 4.National Key Clinical Specialty of Urology, Tianjin Key Lab of UrologySecond Affiliated Hospital of Tianjin Medical UniversityTianjinChina

Personalised recommendations